Seemingly overnight, healthcare discovered and fully embraced digital health solutions. Just months after the 2020 nationwide lockdown, telehealth visits, virtual clinical trials and countless remote patient care technologies became the new normal.
The aftershocks of COVID-19 continue to reverberate throughout the U.S. healthcare system. For example, the pandemic has forever dispelled the quaint notion that “real” healthcare can only occur in hospitals and clinics. By drastically restricting in-person visits, COVID-19 has forced healthcare providers to find new ways to remotely engage, monitor, manage, and treat patients.
The pandemic has set ablaze the white-hot market for Digital Therapeutics (DTx), which “deliver medical interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of diseases and disorders.”
In recent years, there has been a great deal of talk in healthcare circles about remote patient monitoring (RPM), a trend that has only accelerated over the past 18 months with the arrival of COVID-19 and the need, early in the pandemic, to transfer a great deal of care to remote delivery.
In this episode of Medtech Matters, a podcast focused on the medical device manufacturing industry and the factors impacting it, we speak with Russ Johannesson, CEO of Glooko. He speaks about the advantages remote monitoring offers to both physicians of diabetics as well as the patients themselves.
A study assessing use of remote patient monitoring in patients with type 2 diabetes outlines the impact continued participation in digital monitoring programs can have on glycemic control among this patient population.
According to study findings presented by Glooko at the American Diabetes Association (ADA) scientific sessions on Friday, remote patient monitoring (RPM) helped patients with type 2 diabetes achieve improved and sustained glycaemic control.
The company aims to secure a CE mark for the Tempo Smart Button by the end of this year, enabling it and the Tempo Pen to be sold as a single package in European markets.
Glooko will partner with Eli Lilly for a strategic digital health collaboration using Eli Lilly’s connected insulin pens, the Tempo Pen and Tempo Smart Button.
To make sure its upcoming connected insulin pen system will work with the user’s choice of daily diabetes management platforms, Eli Lilly & Co. has signed compatibility agreements with four international providers. That includes glucose monitoring sensors, digital health programs and other tools from Roche, Dexcom, Glooko and myDiabby Healthcare.